Skip to main content

Table 3 Progression-free survival rate after the initiation of immune checkpoint inhibitors

From: ALDH2 polymorphism rs671 is a predictor of PD-1/PD-L1 inhibitor efficacy against thoracic malignancies

Observation period

Restricted mean survival time

 

Rs671(−)

Rs671(+)

0–6 months

0.82

0.58

6–12 months

0.46

0.31

12–24 months

0.25

0.26

24–36 months

0.20

0.26

  1. Rs671(−); ALDH2*1/*1, rs671(+); ALDH2*1/*2 or ALDH2*2/*2